| 摘要 |
An autotaxin(ATX)-lysophosphatidic acid(LPA) signalling pathway modulator for use in treating hepatitis B infection. The modulator may be an antagonist of a G-protein coupled lysophosphatidic acid receptor (LPAR), an inhibitor of hypoxia inducible factor 1 alpha (HIF1α) such as a phosphoinositide 3 kinase (PI3K) or mitogen activated protein kinase (MAPK) or MAPK/MEK inhibitor. Specifically the modulator may be HA130, siRNA targeting of ATX or HIF1α, KM-6425, wortmannin, BYL-719 or TGX-221. |
